ArticleJournal of neurology, neurosurgery, and psychiatry2006
Axon loss is an important determinant of weakness in multifocal motor neuropathy.
Article in Journal of neurology, neurosurgery, and psychiatry, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 84 citations in OpenAlex.
- IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up.Journal of neurology · 2009Trial
- Clinical and electrophysiological features for differentiating MMN from hand-onset ALS.Journal of the Chinese Medical Association : JCMA · 2026Article
- Epidemiology, Patient Characteristics, Real-World Treatment Patterns, and Healthcare Utilization and Spending for Patients with Multifocal Motor Neuropathy: A US Claims-Based Analysis.Journal of health economics and outcomes research · 2026Article
- Prevention of axonal loss after immediate dosage titration of immunoglobulin in multifocal motor neuropathy.European journal of neurology · 2024Article
- IgM anti-GM2 antibodies in patients with multifocal motor neuropathy target Schwann cells and are associated with early onset.Journal of neuroinflammation · 2024Article
- Quantitative MR Neurography in Multifocal Motor Neuropathy and Amyotrophic Lateral Sclerosis.Diagnostics (Basel, Switzerland) · 2023Article
- Motor unit integrity in multifocal motor neuropathy: A systematic evaluation with CMAP scans.Muscle & nerve · 2022Article
- Multifocal motor neuropathy occurring after acute motor axonal neuropathy: two stages of the same disease?Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Quantitative magnetic resonance imaging of the brachial plexus shows specific changes in nerve architecture in chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy and motor neuron disease.European journal of neurology · 2021Article
- Pattern of muscle strength improvement after intravenous immunoglobulin therapy in multifocal motor neuropathy.Muscle & nerve · 2021Article
- Diffusion Basis Spectrum Imaging Detects Axonal Loss After Transient Dexamethasone Treatment in Optic Neuritis Mice.Frontiers in neuroscience · 2020Article
- Noninvasive Quantification of Axonal Loss in the Presence of Tissue Swelling in Traumatic Spinal Cord Injury Mice.Journal of neurotrauma · 2019Article
- MRI shows thickening and altered diffusion in the median and ulnar nerves in multifocal motor neuropathy.European radiology · 2017Article
- Human immune globulin infusion in the management of multifocal motor neuropathy.Degenerative neurological and neuromuscular disease · 2016Review
- Complement activity is associated with disease severity in multifocal motor neuropathy.Neurology(R) neuroimmunology & neuroinflammation · 2015Article
- Sural sparing pattern discriminates Guillain-Barré syndrome from its mimics.Muscle & nerve · 2014Article
- Treatment of multifocal motor neuropathy with intravenous immunoglobulin.Journal of clinical immunology · 2014Review
- The node of Ranvier in multifocal motor neuropathy.Journal of clinical immunology · 2014Review
- Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatment.Neuropsychiatric disease and treatment · 2014Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultifocal motor neuropathy (MMN) is characterised by asymmetrical weakness and muscle atrophy, in the arms more than the legs, without sensory loss. Despite a beneficial response to treatment with intravenous immunoglobulins (IVIg), weakness is slowly progressive. Histopathological studies in MMN revealed features of demyelination and axon loss. It is unknown to what extent demyelination and axon loss contribute to weakness. Unlike demyelination, axon loss has not been studied systematically in MMN. Aims/
methodsTo assess the independent determinants of weakness in MMN, 20 patients with MMN on IVIg treatment were investigated. Using a standardised examination in each patient, muscle strength was determined in 10 muscles. In the innervating nerve of each muscle, axon loss was assessed by concentric needle electromyography, and conduction block or demyelinative slowing by motor nerve conduction studies. Multivariate analysis was used to assess independent determinants of weakness.
resultsNeedle electromyography abnormalities compatible with axon loss were found in 61% of all muscles. Axon loss, and not conduction block or demyelinative slowing, was the most significant independent determinant of weakness in corresponding muscles. Furthermore, axon loss and conduction block were independently associated with each other.
conclusionAxon loss occurs frequently in MMN and pathogenic mechanisms leading to axonal degeneration may play an important role in the outcome of the neurological deficit in patients with MMN. Therapeutic strategies aimed at prevention and reduction of axon loss, such as early initiation of treatment or additional (neuroprotective) agents, should be considered in the treatment of patients with MMN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.